1 completed. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Completed 1 |
Follow PG 545: new trials by email Literature Review of PG 545 trials Research Report on PG 545
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC) Pixatimod, Nivolumab, Cyclophosphamide (low dose) - NSCLC, Metastatic Colorectal Carcinoma | Phase 2 | Completed | Diwakar Davar | 13 | 2021-12-09 | 2026-09-08 |
Colorectal Neoplasms (1) · Melanoma (1)
Diwakar Davar (1)
United States (1)